Our Co-Founder and CEO Selin Kurnaz, PhD was in #Boston for the last three days at the Digital Health & AI Innovation Summit (DHAI). She breaks it all down on her ride to the airport. In this video, she shares her key takeaways from the summit: the growing role of #AI in reducing the administrative burden on physicians, what the revolutionary pancreatic cancer announcement at American Society of Clinical Oncology (ASCO) means for the future of AI-trained models in #oncology, and why measuring the real-world clinical utility of AI algorithms needs to become a priority for the entire industry. Massive Bio was a proud sponsor of the event. Grateful for the conversations, the connections, and the momentum. More updates coming soon. #DigitalHealth #AIinOncology #HealthcareAI #ClinicalAI #Oncology #PrecisionOncology #DHAI

What an incredible two days in Boston. Massive Bio was proud to sponsor the Digital Health & AI Innovation Summit (DHAI) 2026, and even prouder to have two of our co-founders on stage alongside 130 global health AI leaders. Our Co-Founder & Chief Medical AI Officer Arturo LoAIza-Bonilla MD took the Intelligence Revolution Stage on Day 1 to present "AI-Orchestrated Precision Oncology: The Intelligent Patient Journey", making the case for what it truly means to orchestrate AI around the patient, not just the system. Our Co-Founder and CEO Selin Kurnaz, PhD joined the "Augmented Clinicians, Empowered Patients: The Smart Hospital Revolution" panel, bringing her perspective on how AI can make clinicians more powerful without making patients feel like data points. We also had the honor of hosting the opening night reception, kicking off the summit with the conversations that matter most. This is exactly the room Massive Bio belongs in, and we're not done showing up. #DHAI2026 #DigitalHealth #AIinHealthcare #PrecisionOncology #SmartHospitals #ClinicalTrials @MassiveBio | @WorldBI_Uk | @DrArturoAI | @skurnaz

Massive Bio is proud to be a sponsor of the Digital Health & AI Innovation Summit (DHAI) 2026, June 8–9 at the Omni Boston Hotel at the Seaport. Our Co-Founder & Chief Medical AI Officer Dr. Arturo LoAIza-Bonilla MD will be taking the main stage to speak on "AI-Orchestrated Precision Oncology: The Intelligent Patient Journey", a topic at the very core of what we've built at Massive Bio. Joining him in Boston is our Co-Founder and CEO Selin Kurnaz, PhD, as we bring together the vision and the science behind AI-driven cancer care. From trial matching to multi-agent AI, the conversations happening at DHAI reflect exactly what we've been building for 190,000 patients across 17 active markets. Let's connect in Boston. 📍 Omni Boston Hotel at the Seaport | June 8–9, 2026 #DHAI2026 #DigitalHealth #AIinHealthcare #PrecisionOncology #ClinicalTrials

Our Co-Founder and CEO Selin Kurnaz, PhD just wrapped up the @Jefferies Healthcare Investment Conference in New York City, right off the back of ASCO. At Jefferies, the conversations are different. These are top 20 pharma executives sharing their strategic priorities, their pipelines, their outlook. Our goal is always the same: understand where they're headed, and show them how Massive Bio can be their secret weapon in getting the right therapies to the right patients, faster. The through-line? The discoveries coming out of American Society of Clinical Oncology (ASCO) need to reach patients. That's exactly what we do. Next stop: Boston. We're proud to be a sponsor at the Digital Health & AI Innovation Summit (DHAI), hope to see you there. #ASCO2026 #Jefferies #Oncology #ClinicalTrials #DigitalHealth #HealthcareInnovation #PrecisionOncology

Most lung cancer patients flagged at high risk during imaging never make it to a clinical trial. Massive Bio Optellum are closing that gap. Optellum's FDA-cleared AI surfaces high-risk nodule patients early. We match them to active NSCLC trials and get the right information to their physicians, in real time. Full story: massivebio.com/massive-bio-o… #LungCancer #NSCLC #ClinicalTrials #AIHealth

Our Co-Founder and CEO Selin Kurnaz is en route from ASCO 2026 to the @Jefferies Healthcare Investment Conference in New York City, and the momentum from Chicago is following her there. American Society of Clinical Oncology (ASCO) 2026 was a defining week for Massive Bio. Nearly 200 meetings. Four press releases. Six new product launches. Remarkable traction across our clinical, commercial, and real world data business lines, and meaningful engagement with every layer of the oncology ecosystem: FDA, NCI, pharmaceutical companies, payers, providers, and patients. This is what strengthening market leadership looks like. The conference is over but the work continues. #ASCO26 #Oncology #ClinicalTrials #CancerCare #HealthcareInnovation #JefferiesHealthcare

Day 3 at #ASCO2026, and the energy at Booth #IH04 has been incredible. Following yesterday's announcement of the Reticulum Nexus™ product suite, we've had the privilege of connecting with researchers, clinicians, and innovators from across the globe, all united by the same mission: getting the right patients to the right trials, faster. Tomorrow, June 1st, our Co-Founder & Chief Medical AI Officer, Arturo LoAIza-Bonilla MD (@DrArturoAI), will be presenting at Session S403: 🗓 "Practical Playbook for Artificial Intelligence, Screening, and Remote Oncology in Resource-Constrained Settings" 🕤 9:45 - 10:00 AM CDT If you're at McCormick Place, stop by Booth #IH04, we'd love to connect. #ASCO26 #PrecisionOncology #ClinicalTrials #AI #Oncology

ASCO 2026 is here, and so are we. We're live at Booth #IH04 in the Innovation Hub at McCormick Place, #Chicago, and the conversations have already started. The booth is buzzing, the energy is incredible, and seeing so many brilliant minds gathered around one shared mission is exactly why we do this. This year, we're showing what it actually looks like when AI moves beyond matching and into full orchestration. Sentinel Agents™ monitoring in real time. NexusPulse™ Intelligent Calculators turning clinical signals into next actions. DrArturo AI™ and Phoebe AI™ supporting clinicians and patients at every step. TrialRelay™ making sure no referral disappears into the void. All of it connected, all of it inside Reticulum Nexus™. American Society of Clinical Oncology (ASCO) brings the entire oncology ecosystem under one roof, and we're grateful to be part of it, made possible in part by the incredible organizations that make this conference happen, including Bristol Myers Squibb (@bmsnews) , Daiichi Sankyo US(@DaiichiSankyoUS), Genentech (@genentech), Gilead Sciences (@GileadSciences) , Eli Lilly and Company (@EliLillyandCo), and more. If you're here, come find us. Let's talk. Schedule a meeting with us: lnkd.in/d75GFjXV 📍 Booth #IH04, Innovation Hub, McCormick Place #ASCO2026 #PrecisionOncology #ClinicalTrials

Another reason why #ASCO26 is so special is how we all come together to find each other for collaborations, research, science, and R&D. Even better when meeting with @ASCO staff, friends, colleagues, mentors and mentees. Hearts are full, science is shared, the best of humanity represented in the fight against cancer (and of course, AI 😉) @mystlukes @MassiveBio

Today at #ASCO2026, Massive Bio announced the next-generation Reticulum Nexus™ suite, Patient Connect™, TrialRelay™, NexusPulse™, Sentinel Agents™, DrArturo AI™, and Phoebe AI™ working together in real-time to move patients from matching to enrollment. Full announcement: massivebio.com/massive-bio-r… #OncologyAI #ClinicalTrials #PrecisionOncology

Massive Bio has partnered with @TOUCHBBCA and @NavigatingTrials to bring AI-powered clinical trial matching directly to cancer patient communities. Because finding the right trial shouldn't be this hard. Read more: massivebio.com/massive-bio-t… #ClinicalTrials #CancerCare #HealthEquity

At #ASCO2026, Massive Bio is unveiling the next phase of Reticulum Nexus, our multi-agent AI operating system for oncology access. Not a chatbot. Not a dashboard. Infrastructure. Booth #IH04, Innovation Hub. 🔗 massivebio.com/massive-bio-r… 🔗 massivebio.com/asco26?utm_so… #ASCO2026 #OncologyAI #ClinicalTrials

We arrive in #Chicago in 2 days. It's been a milestone year. A landmark peer-reviewed study across 3,800 cancer patients. Our collaboration with @OpenAI. Partnerships with BeeKeeperAI, Just Worldwide (@JWWMedResearch) Worldwide, and more. A Digital Medicine Society (DiMe) Seal recipient and listed in the Centers for Medicare & Medicaid Services Medicare App Library, reaching over 68 million Medicare beneficiaries. And we're not done. Some of our biggest announcements are coming during and after #ASCO2026. Find us at Booth #IH04 in the Innovation Hub, or schedule time with the team before the doors open: 🔗 massivebio.com/asco26?utm_so… 📍 McCormick Place, Chicago · May 29 – June 2 #ASCO26 #OncologyInnovation #ClinicalTrials #PrecisionOncology

We're expanding access to oncology clinical trials for underserved communities, with privacy built in from the start. Massive Bio has deployed its AI-powered pre-screening capabilities through BeeKeeperAI's EscrowAI® platform, leveraging federated confidential computing to match cancer patients to clinical trials without ever moving their sensitive data outside the healthcare provider's environment. The program initially focuses on the #Atlanta, #Georgia region, working to reach historically underrepresented patient populations who may otherwise never learn about trials they qualify for. This is what equitable, scalable clinical research looks like: AI traveling to the data, not the other way around. 🔗 Read the full announcement: massivebio.com/massive-bio-b…

Today, May 20, is International Clinical Trials Day. Clinical trials are how medicine moves forward. But for too long, finding the right trial has been one of the hardest parts of a cancer diagnosis. At Massive Bio, we exist to change that. Our AI has matched over 190,000 patients to clinical trials across 17 countries, so that geography, complexity, and time never stand between a patient and a potentially life-changing option. Every match matters. Every trial matters. Every patient matters. #InternationalClinicalTrialsDay #ClinicalTrials #OncologyInnovation #CancerCare

Germany, we're here. 🇩🇪 Our Co-Founder, CTO & COO Çağatay Çulcuoğlu is at DataForum today in Mainz, joining researchers, clinicians, lawyers, and data infrastructure experts for a full afternoon of talks and hands-on exchange around one of healthcare's most pressing challenges: turning health data into real-world impact. From the EU Health Data Space to real-world evidence, data governance to clinical research infrastructure — the conversations happening today matter deeply to what we build at Massive Bio every day. See you at KUZ. 👋 📅 May 19 | KUZ – Kulturzentrum Mainz, Germany #DataForum #HealthData #DigitalHealth #RealWorldData

Our Co-Founder and CEO Selin Kurnaz, PhD was in #Nashville for the AGC Partners HCIT & Life Sciences Technology Summit, with 16 investor meetings in a single day. The investment landscape for healthcare AI is shifting. Traditional software models are being re-evaluated, consolidation is on the horizon, and the platforms that own a vertical with direct patient-consented data at their core are the ones positioned to lead. Massive Bio is at the center of that shift. Hear Selin's take on what investors are signaling and what it means for the road ahead, and visit massivebio.com/asco26 to see what Massive Bio is bringing to #ASCO2026 and schedule a meeting. #HealthcareAI #Oncology #ClinicalTrials #HealthTech #PrecisionOncology #ASCO2026 #ASCO26

Massive Bio and Just Worldwide are partnering to connect more cancer patients to clinical trial opportunities — through patient communities, advocacy groups, and AI-driven trial matching. Only 3–5% of cancer patients ever enroll in a clinical trial. The barrier is rarely eligibility. It is awareness, access, and trust. Just Worldwide brings deep engagement with patient communities — including underrepresented populations — at a scale that traditional recruitment methods cannot reach. Massive Bio brings the AI infrastructure to match those patients to the right trials at the right moment. Together, we are closing the gap between patients who qualify and trials that need them. "As oncologists, we know that the right clinical trial can be a turning point for a patient — but only if they know it exists. Just Worldwide's ability to engage patients and advocacy communities at scale, combined with Massive Bio's AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey." — Arturo Loaiza-Bonilla, MD, Co-Founder & Chief Medical AI Officer, Massive Bio 🔗 massivebio.com/massive-bio-j… @MassiveBio @JWWMedResearch @DrArturoAI #ClinicalTrials #Oncology #AIinOncology #CancerCare #PatientAccess #HealthEquity #PrecisionOncology